Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? [2]

AIDS

Volumn 16, Issue 2, 2002, Pages 296-297

  Mauss, Stefan ^a   Schmutz, Guenther ^a   Kuschak, Dieter ^b  

^a HIV Specialized Practice   (Germany)

^b Medizinische Laboratorien Duesseldorf   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; LOPINAVIR; RITONAVIR;

DRUG BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; STEADY STATE; TREATMENT FAILURE;

CARBAMATES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PILOT PROJECTS; PYRIMIDINONES; RITONAVIR; SULFONAMIDES;

EID: 0037169211     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201250-00023     Document Type: Letter

References (4)

1. Amprenavir plasma concentrations are dramatically increased by association with ritonavir baby-doses in HIV-infected patients
2. Enhancement of pharmacokinetic parameters of amprenavir when combined with low dose ritonavir (APV 600 mg/RTV 100 mg BID) and preliminary efficacy results
3. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by gradient HPLC
4. Unexpected drug-drug interaction between amprenavir and ritonavir